Merck and Sanofi sound the alarm for ILT inhibition
Merck & Co gives up on Agenus, while Sanofi hands BND-22 back to Biond.
Vir shows up Sanofi
Two masked bispecific antibodies, licensed for $100m, produce promising early data.
ASH 2024 – J&J aims at a myeloma precursor
The Aquila study could make Darzalex the first approved drug for smouldering multiple myeloma.
Sanofi goes deeper into the lead
The French group takes a shot at Perspective with its second bet on Orano Med.
BeiGene tries where others failed
The company’s CEACAM5 and PRMT5 projects feature among the latest first-in-human entrants.
World Lung 2024 – a way forward for CEACAM5?
Patients' expression of CEACAM5 might hold the key to activity after all.
